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doi:10.101Expansion of NKG2A–LIR1– Natural Killer Cells in HLA-
Matched, Killer Cell Immunoglobulin-Like Receptors/
HLA-Ligand Mismatched Patients following
Hematopoietic Cell Transplantation
Silvia Rathmann,1,2 Sabine Glatzel,1,2 Kathrin Scho¨nberg,3 Markus Uhrberg,3 Marie Follo,1
Christian Schulz-Huotari,4 Markus Kaymer,5 Hendrik Veelken,1 Ju¨rgen Finke,1 Paul Fisch2The prognosis after hematopoietic cell transplantation (HCT) for the treatment of leukemia or lymphoma in
humans is influenced by donor-derived natural killer (NK) cells, which enhance the graft-versus-leukemia
(GVL) effect. Such alloreactive killer cells can be generated in vivo after HCT if the donor expresses killer
cell immunoglobulin-like receptors (KIRs), such as KIR2DL1, KIR2DL2/3, or KIR3DL1, for which the recip-
ient lacks HLA class I ligands. We studied effector cells from 22 KIR/HLA-ligand mismatched and 14 KIR/
HLA-ligand matched, primarily HLA-matched patient-donor pairs after allogeneic HCT. A novel 8-color
flow cytometry panel allowed us to characterize effector-cell populations without ‘‘broadly reactive’’ inhib-
itory receptors such as CD94/NKG2A or LIR1. The numbers of such NKG2A– LIR1– NK cells increased fol-
lowing HCT in patients transplanted by KIR/HLA-ligand mismatched grafts, compared to KIR/HLA-ligand
matched grafts, and in patients transplanted from donors of the A/B, compared to A/A, KIR haplotypes.
NKG2A–LIR1– NK cells expressing only those inhibitory KIRs for which the patient had no HLA class I ligands
could be stimulated by HLA class I-deficient cells to express CD107a. Thus, NKG2A–LIR1– NK cells may be
important GVL effector cells following HCT, even in patients transplanted from HLA-matched donors.
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mismatchINTRODUCTION
Allogeneic hematopoietic cell transplantation
(HCT) is often the only possibility to cure acute mye-
logenous leukemias, myelodysplastic syndromes, and
aggressive leukemias/lymphomas. A key to survival in
this situation is the graft-versus-leukemia (GVL) effect,
mediated by effectors from the donor that destroy re-
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6/j.bbmt.2009.12.008nor-derived natural killer (NK) cells, which have been
shown to play an important role in the outcome of al-
logeneic HCT [1,2]. The function of NK cells is regu-
lated by the balance of signals from clonally distributed
inhibitory and activating cell surface receptors [3]. The
same receptors can be expressed on resting or activated
gd and abT cells [4]. The most important ones are the
inhibitory NK receptors, which induce tolerance
against self. These include the lectin-like receptor
CD94/NKG2A, which is specific for the nonclassical
class I molecule HLA-E, and is stabilized by leader
peptides from most classical HLA-A, -B, and -C allo-
types [5]. The Ig-like receptors, encoded in the leuko-
cyte receptor complex of chromosome 19, can be
divided into the killer cell immunoglobulin-like recep-
tors (KIRs) and the leukocyte Ig-like receptors [6]. The
leukocyte Ig-like receptors (CD85), previously called
immunoglobulin-like transcripts or leukocyte immu-
noglobulin-like receptors (LIR), are broadly reactive
inhibitory receptors against the HLA-A, -B, and -C al-
lotypes. Similar to CD94/NKG2A, they enable NK
cells to survey for overall class I expression [7]. In con-
trast, 3 different KIRs can distinguish between groups469
Table 1. Characteristics of the KIR-Ligand Mismatched and
KIR-Ligand Matched HCT Patients
KIR-Ligand
Mismatch
KIR-Ligand
Match
N 22 14
Age 62.5 ± 8 56.5 ± 15
Sex (male / female) 18 / 4 6 / 8
Diagnosis (n) AML/MDS 5 16 AML/MDS 5 9
B-NHL 5 6 B-NHL 5 5
HLA class I mismatch in GVHD
direction (n)
A 0 0
B 0 0
C 3 1
KIR haplotype (n)
A/B 14 5
A/A 7 4
B/B 1 5
Transplantation (n)
Related 5 (23%) 9 (64%)
Unrelated 17 (77%) 5 (36%)
AML indicates acute myelogenous leukemia; MDS, myelodysplastic syn-
drome; NHL, non-Hodgkin lymphoma; GVHD, graft-versus-host dis-
ease; KIR, killer cell immunoglobulin-like receptor.
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ognize HLA-C allotypes with a lysine at position 80
(C2 ligands such as Cw02, 0307, 0310, 04, 05, or 06).
KIR2DL2 and KIR2DL3 recognize HLA-C allotypes
with an asparagine at position 80 (C1 ligands, such as
Cw01, 03, 07, or 08). KIR3DL1 molecules recognize
HLA-B-allotypes with a polymorphic sequence motif
at position 77-83 (Bw4 epitope), whereas KIR3DL2 in-
teracts with the HLA-A3 and A11 allotypes.
Besides inhibition, NK cells require activation by
virus-infected or leukemic cells to mediate their protec-
tive functions [11,12]. Stimulatory receptorsonNKcells
include lectin-like receptors suchasCD94/NKG2Cand
the KIRDS molecules. The HLA class I specificities
and antibody reactivities of activating KIRs overlap
with those of the corresponding inhibitory KIRs. Other
activating receptors onNKcells are theNKG2Dhomo-
dimers whose ligands include MHC class-I-related
chain A/B (MICA/B) [13]. A third class of activating re-
ceptors on NK cells, as well as some T cells, are the
natural cytotoxic receptors (NCR), NCR1 (NKp46),
NCR2 (NKp44), and NCR3 (NKp30) [9]. Although
the ligands for these receptors have not been fully eluci-
dated, they may be important in the recognition of
leukemic cells [9,11,12]. Inhibitory NK receptor signals
generally overrule signaling through stimulatory recep-
tors [10,14]. Several clinical studies demonstrated im-
proved survival post allogeneic HCT, along with
a strong GVL effect against myelogenous leukemias
when the patient was lacking 1 of the 3 major KIR/
HLA-ligands present in the donor, the Bw4 epitope in
HLA-B, or the C1 or C2 ligands in HLA-C [1,15-20].
The likely mechanism for this is that NK cells derived
from the graft express a ‘‘leukemia-reactive’’ profile of
inhibitory receptors. These inhibitory KIR do not find
an HLA class I ligand on the recipient’s cells, including
residual leukemia cells. Because all KIRs are encoded on
chromosome 19, they are segregated independently of
the HLA alleles on chromosome 6. Thus, transplants
from HLA identical family donors may be KIR-
mismatched [21], whereas only transplants from identi-
cal twins are HLA- and KIR-matched. We studied
regenerating NK and T cells following allogeneic
HCT in adult patients, most of which were HLA-
matched. According to the expression of KIRs in the
donor’s blood, the patients were divided into KIR/
HLA-ligand matched and mismatched groups. In an
effort to better understand the GVL effect we focused
our analysis on the regenerating NK cells without ex-
pression of broadly reactive inhibitory NK receptors
(CD94/NKG2A and LIR1 [CD85j]) and monitored
their regeneration in KIR/HLA-ligand matched as
well as mismatched patients post-HCT. In addition,
we monitored NK receptor expression on other innate
effector cell populations that may be relevant for the
GVL effect postallogeneic HCT, such as NKT cells,
NKT-like cells, and gdT cells.MATERIALS AND METHODS
Patients
The study included 36 consecutive adult patients
treated by allogeneic HCT in the Division of Alloge-
neic Stem Cell Transplantation, Department of He-
matology/Oncology, Freiburg University Hospital.
The details of their transplant history are given in
Tables 1, S1, and S2. This study was approved by the
University of Freiburg Hospital Ethics Committee;
all clinical investigations were conducted according
to the Declaration of Helsinki Ethical Principles.
The patients provided informed written consent prior
to inclusion in this study. All patients received granu-
locyte colony-stimulating factor (G-CSF) mobilized
peripheral blood progenitor cells from HLA A-, B-,
and C-locus matched donors (32 patients) or HLA
A-, B-locus matched, but C-locus mismatched donors
(4 patients). The patients were only considered C-lo-
cus mismatched if the donor and recipient were as-
signed to different HLA-C allele groups (C1 or C2).
For the purpose of this study we assigned the patients
to the groups ‘‘KIR/HLA-ligand match’’ and ‘‘KIR/
HLA-ligand mismatch,’’ as defined shortly.
Sample Collection and Preparation
Blood samples were drawn from donors and recip-
ients before and after transplantation. The blood sam-
ples post-HCT were collected on days 14 (n5 36), 28
(n5 35), 56 (n5 35), 84 (n5 33), 112 (n5 30), 140 (n
5 29), 168 (n5 31), 252 (n5 16), and 336 (n5 1). All
blood samples were drawn within 1 week of the speci-
fied day. In the case of missed collections, samples
were obtained at interim time points whenever
Biol Blood Marrow Transplant 16:469-481, 2010 471NKG2A–LIR1– NK Cells following HCTpossible. Three relapsed patients were excluded from
further analysis when they had to undergo a second
transplantation. All blood samples were freshly pro-
cessed by isolation of peripheral blood mononuclear
cells (PBMCs) on Ficoll gradients (LSM 1077, PAA,
Pasching, Austria), followed by staining for flow cy-
tometry analysis.
KIR-Polymerase Chain Reaction (PCR)
Genotyping
Donor DNA samples were extracted using
QIAamp DNA Blood Mini kit (Qiagen, Hilden,
Germany). KIR genotyping was performed according
to published protocols with minor modifications
[20,22] to differentiate inhibitory KIRs from activating
KIRs (KIR2DL1/S1, KIR2DL2/S2, KIR2DL3/S3,
KIR2DL5, KIR3DL1/S1, KIR3DL2) and determine
the KIR haplotypes.
Antibodies and Flow Cytometry
The following mouse antihuman monoclonal anti-
bodies (mAbs) were used: CD3-FITC (UCHT1),
TCRgd-FITC (IMMU 510), NKG2A-PE (Z199),
CD85j-PE (HP-F1), TCR Va24-FITC (C15),
NKG2D-PE (ON72), NKp30-PE (Z25), NKp44-
PE (Z231), NKp46-PE (BAB281), CD3-ECD
(UCHT1), CD244-PE-Cy5 (C1.7.1), CD56-PE-Cy7
[N901(NKH-1)], CD158a,h-APC (EB6.B) (all from
Beckman Coulter, Krefeld, Germany), and TCRab-
FITC (BMA031) (Serotec, Oxford, UK). The mAb
TCR Vb11-PE-Cy7 (C21), CD158e-ECD (Z27),
and CD158b,j-APC-Cy7 (GL183) were purchased as
custom-conjugates (Beckman Coulter, Custom De-
sign Service). For surface staining, PBMC were incu-
bated with different mAb panels, as shown in Table
S3. Following 15 minutes of incubation, 50 mL of Op-
tiLyse B solution (Beckman Coulter) were added for
red cell lysis. After 15 minutes 500 mL of double-dis-
tilled water (Braun, Melsungen, Germany) were added
and the tubes were incubated for a further 20 minutes.
The samples were washed (PBS 1 1% human serum),
fixed in 250 mL 1% paraformaldehyde (IOTest 3 Fix-
ative Solution; Beckman Coulter), and events were ac-
quired on a CyAn ADP Flow Cytometer (Beckman
Coulter). Voltage of the CyAn FlowCytometer was
first adjusted using appropriate isotype controls for
each color. Then, compensation beads for each color
(antimouse Ig CompBeads, BD) were run on the in-
strument. Upon analysis of the surface markers auto-
matic compensation was preformed using the FlowJo
(Tree Star, Ashland, OR, USA) program.
CD107a and Interferon (IFN)-g Assay
PBMC were incubated in complete medium
(IMDM, supplemented with L-Arginine, L-Aspara-
gine, L-Glutamine, penicillin, streptomycin [allfrom Gibco, Invitrogen, Karlsruhe, Germany] and
heat-inactivated 10% male human serum [PAN-
Biotech, Aidenbach, Germany]) for 4 hours at 37C
in the presence of monensin (GolgiStop; BD) the
CD107a-PE-Cy5.5 mAb (H4A3) (Beckman Coulter,
Custom Design Service) [23-25] and K562 cells
(50.000 K562/150.000 PBMC). Then, the cells were
washed (phosphate-buffered saline [PBS] 1 1% hu-
man serum), stained for surface markers (30 minutes),
fixed, and permeabilized by IntraPrep Permeabiliza-
tion Reagent (Beckman Coulter). For intracellular
staining we used the IFN-g-Pacific Blue mAb
(4S.B3) (eBioscience, Frankfurt, Germany). Following
30 minutes of incubation, the cells were washed, resus-
pended in 250 mL IOTest 3 Fixative solution (Beck-
man Coulter) and analyzed (8 colors) on an LSR II
cytometer using automatic compensation and the
Diva software (BD Biosciences).Definition of KIR/HLA-Ligand Match and KIR/
HLA-Ligand Mismatch
Donor-recipient pairs were divided into the
categories ‘‘KIR/HLA-ligandmatch’’ and ‘‘KIR/HLA-
ligand mismatch’’ according to the receptor (KIR)-
ligand (HLA) model [17,18]. Using high-resolution
HLA typing all patients were assigned to C1, C2, or
C1/C2 groups (HLA-C) and to the Bw4 group
(HLA-B). In addition, donors’ PBMC were examined
by multicolor flow cytometry for NK cells expressing
KIR2DL1/S1 (C2-specific), KIR2DL2/DL3/S2 (C1-
specific), or KIR3DL1/S1 (Bw4-specific) (Table S4).
A patient was assigned to the group ‘‘KIR/HLA-
ligand match’’ if the KIR expressed by the donor’s
NK cells matched the patient’s HLA-C or -Bw4 li-
gands. Thus, most patients in the KIR-ligand matched
group expressed all 3 KIR ligands C1, C2, and Bw4. In
contrast, a patient was assigned to the group ‘‘KIR/
HLA-ligand mismatch’’ if the donor had NK cells ex-
pressing KIR for which the patient had no HLA-C or
Bw4 ligand. This would mean that there was a KIR-
mismatch in the graft-versus-host (GVH) direction.
Although patients #14 and #18 were missing HLA
C2 KIR ligands, they were assigned to the KIR/
HLA-ligand match group because phenotypic analysis
of their donors’ effector cells failed to demonstrate
KIR2DL1 expression [26].Statistical Analyses
For a statistical comparison of the study groups
20,000 viable lymphocytes were collected per sample.
All data were analyzed using SPSS software (Version
14.0 SPSS, Munich, Germany). The significance of
the differences in cell counts between donor and recip-
ient pairs following HCT were tested using the non-
parametric Mann-Whitney U-test.
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A New 6-Color Flow Cytometry Panel
Differentiating NK and T Cell Subpopulations
We used special mAb panels to characterize inhib-
itory receptors on NK and T cells (Table S3, panels 1-
4). To identifyMHCunrestricted effector cells, we first
gated on the NKG2A– LIR1– effector cells and, alter-
natively, on effector cells that expressed either
NKG2A or LIR1. Then, we identified the NK
(CD3– CD561) (panel 1), NKT-like (TCR ab1
CD561) (panel 2), gd T cell (TCR gd1) (panel 3),
and NKT (Va241 Vb111) (panel 4) cell subsets within
this population. Because both NKG2A/CD94 and
LIR1 (CD85j) represent inhibitory receptors with
broad reactivity against different HLA class I alleles,
we designatedNKG2A– LIR1–NK cells as ‘‘potentially
alloreactive.’’ The NKG2A– LIR1– NK cell subset
was further gated on cells which were single-, double-,
or triple-positive for KIR2DL1/S1 (CD158a,h),
KIR2DL2/L3/S2, (CD158b,j), and KIR3DL1/S1
(CD158e). In addition, we used 4- or 5-color flow cy-
tometry to investigate the expression of activating re-
ceptors NKG2D, CD244 (2B4), NKp30, NKp44,
andNKp46 on each of these effector cell subsets (Table
S3, panels 5-8).NKG2A– LIR1– NK Cells in the Course of HCT
Initially, we compared patients before HCT and
their healthy donors for the presence of MHC
unrestricted killer cells without broadly reactive NK-
inhibitory receptors, designated here the NKG2A–
LIR1– phenotype (Figure 1A). Only NK cells of the
NKG2A– LIR1– phenotype, but not NKG2A– LIR1–
NKT-like T cells or gd T cells, were decreased in
the patients before HCT, when compared to the
healthy donors (P\ .001). In contrast, donors and pa-
tients had similar levels of NK cells expressing 1 or
both of the broadly reactive NK inhibitory receptors
NKG2A and LIR1 (Figure 1B). NKG2A– LIR1– NK
cells were already detectable in the donors and became
a prominent NK cell subpopulation in the late time
course following HCT in some of the patients
(Figure 2). There was a relatively sharp rise of
NKG2A– LIR1– NK cells between days 28 and 84
post-HCT. Although NKG2A– LIR1– NK cells
were, overall, a relatively small population, compared
to NK cells expressing NKG2A and/or LIR1, this
population continued to rise until approximately day
112 post-HCT, when the levels of the other NK cells
were decreasing (Figure 3). As determined by donor
KIR genotyping, increased levels of NKG2A– LIR1–
NK cells post-HCT were more prominent in patients
of the A/B than A/A haplotypes, but there was no ap-
parent difference in the levels of NKG2A1 and/or
LIR11 NK cells (Figure 3). Interestingly, patients re-maining in complete remission (CR) had significantly
more NKG2A– LIR1– NK cells, but not NKG2A1
and/or LIR11NK cells, compared to relapsed patients
as observed at 3 independent time points following
HCT (Figure 4).Increased NKG2A– LIR1– NK Cells in KIR/HLA-
Ligand Mismatched Patients following HCT
Wemonitored NKG2A– LIR1– NK cells from day
14, up to day 168 post-HCT (Figure 5). Assignment of
the patients to the ‘‘KIR/HLA-ligand match’’ and
‘‘mismatch’’ groups was performed according to the
‘‘KIR/HLA-ligand model’’ (see the Methods section)
[18,26]. We noticed significantly increased levels of
NKG2A– LIR1– NK cells in the blood of the KIR/
HLA-ligand mismatched patients compared to the
matched patients (Figure 5). This difference was
mainly caused by an increase in the amount of
NKG2A– LIR1– CD56-dim NK cells (Figure S1a).
Nevertheless, the KIR/HLA-ligand mismatched pa-
tients also had a tendency toward higher levels of
NKG2A– LIR1– CD56-bright NK cells after HCT
than the matched patients (Figure S1b). These statisti-
cally significant differences were present at several in-
dependent time points following HCT, suggesting
that these were biologically relevant.
Next, we analyzed the NKG2A– LIR1–NK cells in
more detail with regard to expression of the relevant
KIR, as well as functional capacity using 8-color flow
cytometry. NKG2A– LIR1– NK cells expressing KIR
for which the patient had no HLA class I ligand (des-
ignated KIR-mismatched NK cells) were detectable
at relatively low levels before HCT. Following HCT
these KIR mismatched NK cells increased in most
patients to higher levels than observed in the particular
donors with the 2 representative patients shown in
Figure 6. Patient #21 had 2 KIR/HLA-ligand mis-
matches in the presence of anHLA-C group mismatch
(donor C1/C2 and patient C2/C2), whereas patient
#28 was HLA identical to his donor but still had
a KIR3DL1-Bw4 mismatch (Tables 2 and S1). Be-
cause the donors for patients #21 and #28 did not carry
KIR3DS1, all NK cells expressing KIR3DL1/S1 in
these patients following HCT expressed the inhibitory
form KIR3DL1. However, patient #21 carried the
KIR2DL2/3 and KIR2DS2/3 genes; therefore, both
forms of this receptor could be expressed by the single
KIR2DL2/L3/S21 cells in this patient. We examined
the functional activity of these potentially alloreactive
NK cells by measuring their surface CD107a expres-
sion and IFN-g secretion following stimulation by
K562 cells [23-25]. NKG2A– LIR1– NK cells express-
ing the mismatched KIRs, as well as other inhibitory
KIRs (marked by an arrow in Figure 6A) could clearly
be stimulated by K562 cells, revealing their alloreac-
tive potential against target cells that did not express
Figure 1. Characterization of effector cells positive or negative for NKG2A/LIR1 inhibitory receptors in patients before HCTand their donors. The
numbers of NK cells, NKT-like cells (TCR ab1, CD561) and gd T cells were gated on (A) all NKG2A– LIR1–, as well as on (B) NKG2A1 and/or LIR11
effector cells. ‘‘NKG2A1 and/or LIR11 effector cells’’ include the NKG2A1 LIR1–, the LIR1– NKG2A1, and the LIR11 NKG2A1 cell populations. Cell
numbers were determined by flow cytometry from a total of 20,000 cells in patients beforeHCTand their donors. Highly statistical significant differences
(Mann-Whitney U-Test) (P\.001) are indicated by **.
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(Figure 6B). In addition, we gated on NKG2A–
LIR1– NK cells that expressed only the mismatched
KIR but none of the KIR/HLA-ligand matched inhib-
itory or activating receptors because such NK cells
should find no inhibitory HLA class I ligands on the
patient’s leukemia cells. Remarkably, even these single
mismatched KIR1NK cells appeared to be functionaleffector cells showing a 2- to 4-fold increase in
CD107a expression while there was some, albeit lower,
induction of INF-g secretion.
Activating Receptors on NK Cells Post-HCT
Besides analysis of the diverse KIR, NKG2A, and
LIR1, we studied expression of the activating receptors
NKG2D, 2B4, NKp30, NKp44, and NKp46 on
Figure 2. NKG2A/LIR1 expression on NK cells of representative KIR/HLA-ligand mismatched donor/patient pairs. The NK cells of particular donors
and representative patients #28, #30, and #34 were analyzed for NKG2A/LIR1 expression by gating on CD32 CD561 lymphocytes before HCT (pre
Tx) and at different time points following HCT.
474 Biol Blood Marrow Transplant 16:469-481, 2010S. Rathmann et al.patients’NK cells using separatemAb panels (Figure 7,
Table S3, panels 5-8). The mean-fluorescence index
(MFI) was more informative than percentages of posi-
tive cells because most NK cells expressed NKG2D,
2B4, and NKp46, whereas NKp44 was only expressed
by the CD56-bright NK cells (Figure 7, and data not
shown). During the observation period (168 days)
there was a remarkable increase in the expression levels
of NKG2D in both KIR/HLA-ligand matched as well
as mismatched patients, although it appears that the
KIR/HLA-ligand mismatched patients might have
transiently higher expression levels of NKG2D than
KIR/HLA-ligand matched patients. Similarly, the ex-
pression levels of NKp30, NKp44, and NKp46 in-
creased following HCT, and this phenomenon was
observed in both the KIR/HLA-ligand mismatched
and matched patients. These expression levels were
measured on all NK cells because gating on the
NKG2A– LIR1– NK cell subpopulation would have
involved additional customized mAb that were un-
available at the time of our study.
NK Receptor Expression on T Cells Post-HCT
Besides typical NK cells we also measured the
blood percentages of the other effector cell subsets
(NKT-like, gdTcells, abTcells) and their differential
expression of KIR (Table S3). The percentages of
NKT cells and gd T cells in our patients were rather
low compared to NK cells (data not shown). KIR ex-
pression on these subsets increased posttransplant in
only a few of the patients. Typical NKT cells
(Va241 Vb111) were extremely rare in the patients’
and donors’ blood. Therefore, the amount of bloodobtained and the samples stained did not allow detailed
analysis of the NKT cells. However, when staining
more lymphocytes we found that most Va241
Vb111 NKT cells expressed KIRs, whereas T cells
that were single positive for Va24 or Vb11 did not
(data not shown). Naturally, conventional ab T cells
of donor origin increased in these patients post-
HCT, but KIR expression on these ab T cells was
only noticed in exceptional patients.DISCUSSION
In normal donors 20% to 50% of NK cells belong
to the NKG2A– LIR1– subset, whereas approximately
40% to 50% of NK cells express NKG2A and 15% to
50% LIR1, representing nonoverlapping NK cell sub-
sets (our unpublished results). To our knowledge,
KG2A– LIR1– NK cells have not been specifically ex-
amined to date [19,27]. This subset was increased in
healthy donors compared to the patients before
HCT, in patients that remained in remission com-
pared to relapsed patients, and in KIR-ligand mis-
matched patients compared to KIR/HLA-ligand
matched patients. Interestingly, there was no differ-
ence between patients in remission and relapsed pa-
tients in the percentages of NKG2A1 NK cells. The
most straightforward interpretation of our observa-
tions is that NKG2A– LIR1–NK cells play a protective
role in the GVL effect. The tendency toward signifi-
cance of different NKG2A– LIR1– NK cell numbers
in KIR/HLA-ligand mismatched and matched
patients was already present by days 56 and 84 post-
HCT (Figure 5). Because at these time points most
Figure 3. NK cell levels following HCTanalyzed by the donor KIR haplotype. The numbers of (A) NKG2A– LIR1– NK cells and (B) NKG2A1 and/or
LIR11NK cells, determined from a total of 20,000 effector cells by flow cytometry at different time points following HCT, were analyzed in the donors
and their recipients according to the A/B and A/A KIR haplotypes. Patients of the B/B haplotype were not included in this analysis because 5 of 6 B/B
patients were KIR-ligand matched.
Biol Blood Marrow Transplant 16:469-481, 2010 475NKG2A–LIR1– NK Cells following HCTpatients were still in clinical remission, this suggests
that decreasing percentages of NKG2A– LIR1– NK
cells preceded leukemic relapses and not vice versa.
Thus, higher numbers of antileukemic NK cells may
be important for maintaining remission in the time pe-
riod after day 112. Extrapolating from these data we
propose that the adoptive transfer of donor NK cells
[28] at some point during the time period between 1
and 3months after HCTmay protect against leukemiarelapse, and that prophylactic infusions of enriched
NKG2A– LIR1– NK cells may be particularly protec-
tive. Furthermore, we observed that expansion of
NKG2A– LIR1–NK cells was more evident in patients
with the A/B haplotype than in patients with the A/A
haplotype. However, there was no apparent difference
in the post-HCT rise of the NKG2A1 and/or LIR11
NK cells associated with the different KIR haplotypes
(Figure 3). Patients with A/B KIR haplotypes carry
Figure 4. Effector cells positive or negative for NKG2A/LIR1 inhibitory receptors in the posttransplant course. The numbers of NKG2A– LIR1– NK
cells as well as NKG2A1 and/or LIR11NK cells in patients in CR and in relapse were measured by flow cytometry on days 112, 140, and 168 following
HCT. ‘‘NKG2A1 and/or LIR1 1 NK cells’’ include the NKG2A1 LIR1–, the LIR1– NKG2A1, and the LIR11 NKG2A1 subpopulations. The number of
patients (n) in both groups at each of these time points is shown on the right. Statistically significant differences (Mann-Whitney U-test) (P\.05) are
indicated by * and highly significant differences (P\.001) are indicated by **.
476 Biol Blood Marrow Transplant 16:469-481, 2010S. Rathmann et al.a greater diversity of HLA allele-specific inhibitory
and activating receptors than A/A or B/B patients.
The presence of the A-haplotype with allele-specific
inhibitory KIRs may be required for education of
NKG2A– LIR1– NK cells because these cells express
less inhibitory receptors than NKG2A1 and/or
LIR11 NK cells. In addition, the presence of activat-
ing KIR-genes in the B-haplotypes may enhance NK
cell proliferation and the GVL effect [29,30].
Most of theNKG2A– LIR1–NK cells that were in-
creased in the KIR/HLA-ligand mismatched patients
were of the CD56-dim phenotype (Figure S1).
CD56-dim NK cells are the more cytotoxic NK cell
subset, naturally expressing lower levels of NKG2A
than CD56-bright NK cells that produce cytokines
[31]. The NKG2A– LIR1– NK cells could be consid-
ered developmentally immature, but this probably
only applies to NKG2A– LIR1– KIR– NK cells that
produce less IFN-g and lack cytotoxic potential [32].Figure 5. Comparison of NKG2A– LIR1– NK cell subpopulations in KIR/H
LIR1– NK cells were measured in KIR/HLA-ligand mismatched and KIR/HLA-lig
time points following HCTuntil day 168. The numbers of all NKG2A– LIR1– NK
For each time point, the numbers of patients (n) analyzed in the KIR/HLA-ligan
ferences between the groups are indicated by * (Mann-Whitney U-test).However, the vast majority of the NKG2A– LIR1–
NK cells are matureNK cells because they express var-
ious KIRs and are functional effector cells against
HLA deficient target cells (Figure 6). The engrafted
NKG2A– LIR1– NK cells expressing KIRs for which
the patient had no HLA class I ligand also increased
post-HCT and remained at these levels for at least 6
to 9 months, suggesting that their GVL effect is main-
tained for a long period of time [33,34]. The potential
for alloreactivity by single KIR1NKG2A– LIR1– NK
cells was documented for several patients using the
CD107a assay following stimulation by K562 cells
[23] (Figure 6). These experiments confirmed that, re-
gardless of potential expression of an activating KIR,
these were functional alloreactive NK cells. In a recent
related study [35], single KIR1NK clones from trans-
planted pediatric patients were tested for lysis of autol-
ogous leukemia cells using conventional 51-Cr release
cytotoxicity assays. Our CD107a flow cytometry assayLA-ligand mismatched and KIR/HLA-ligand matched patients. NKG2A–
and matched transplanted patients before HCT (pre Tx) and at different
cells from a total of 20,000 lymphocytes for each patient are compared.
d mismatched and matched groups are given. Statistically significant dif-
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Table 2. Clinical Details of KIR-Ligand Mismatched Transplanted Patients #21 and #28WhoWere Examined in Detail in Figure 6
# 21 # 28
Age/sex 57/f 52/m
Diagnosis MDS MDS
Disease status at HCT untreated untreated
Donor type unrelated unrelated
KIR ligand (donor) C1,C2 C1,C2
KIR ligand (patient) C2 C1,C2
KIR haplotype (donor) A/B A/A
Inhibitory KIR (donor) 2DL1,2DL2/3,3DL1 2DL1,2DL3,3DL1
Activating KIR (donor) 2DS2/3 No
KIR-ligand mismatch KIR2DL2/3 - HLA-C1
KIR3DL1 - HLA-Bw4
KIR3DL1 - HLA-Bw4
GVHD (acute) Grade 1 (skin) Grade 4 (skin, gut)
GVHD (chronic) mild day +192 (skin) severe day +179 (gut) until day +195
Donor chimerism Yes Yes
Outcome CR (+32 months)
Alive
CR (+30 months)
Alive
MDS indicates myelodysplastic syndrome; f, female; m, male; CR, complete remission; KIR, killer cell immunoglobulin-like receptor; HCT, hematopoietic
cell transplant; GVHD, graft-versus-host disease.
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subpopulations that have not been activated by IL-2
in vitro directly upon isolation from the patients’
blood. Expression of CD107a on the surface of NK
cells correlates with degranulation following stimula-
tion and represents a sensitive marker of NK cell activ-
ity [23,36]. Testing autologous leukemia cells for ‘‘the
lack of inhibition’’ of NK cell lysis by a missing HLA
class I ligand offers, in our opinion, no definitive ad-
vantage to K562 cells. Nevertheless, K562 cells differ
from autologous leukemia cells in the spectrum of li-
gands for NK activating receptors, most of which are
yet uncharacterized [11,12]. Autologous leukemia cells
were only available in a few patients, and are frequently
contaminated by normal bone marrow cells. These
facts and the condition of the leukemia cells following
thawing prevented meaningful functional experiments
in our system. This may be why other studies used
fresh allogeneic leukemia cells as well as the HLA class
I A, B, and C negative Epstein-Barr virus transformed
B cell line .221 as target cells [34].
The GVL effect by NK cells implies that leukemia
cells express ligands for activating NK receptors.
Because ligands for these receptors on leukemia cells
remain poorly characterized [9,11,12], it is still impos-
sible to predict which patients’ leukemia cells will be
GVL targets. Although the expression of activating re-
ceptors on leukemia cells cannot be influenced, it is
possible to select donors expressing an inhibitory
KIR without a corresponding HLA class I ligand onFigure 6. Subpopulations of NKG2A– LIR1– NK cells expressing individual KIR
cells, expressing different KIR, from KIR/HLA-ligand mismatched patients #21
pared to their donors. NK cell subsets expressing the KIR for which the patient
and intracellular IFN-g secretion following stimulation by medium or K562 ce
LIR1– NK cells from patients #21 (days 331 post-HCT) and #28 (day 357) (subs
had noHLA class I ligands (outlined by a frame). The percentages of positive cell
dot plots included NKG2A– LIR1– NK cells expressing other inhibitory KIR.
expressing the mismatched KIR as their only inhibitory receptors (for patie
S11) (for the KIR genotype see Tables 2/S1).
=the recipient’s leukemia cells [37]. This can occur in
both the HLA-mismatched or HLA-matched setting
of HCT. Nevertheless, most studies on the protective
role of potentially alloreactive NK cells were
conducted in the haploidentical setting of HCT
[15,17,33-35,38-40] or investigated both HLA-
matched and mismatched patients [19,20]. Only
a few groups have focused their analysis on HLA-
matched patients or HLA-identical siblings
[18,21,30,41,42]. However, there is clearly a lower in-
cidence of treatment related complications following
HLA matched allogeneic HCT [37], whereas a mis-
match at a single or multiple loci is associated with
higher treatment-related mortality and graft-
versus-host disease, regardless of other factors such
as patient age, disease status, or use of T cell depletion
[43]. For fully HLA-matched patients, haplotype
matching seems to further decrease the likelihood of
severe graft-versus-host disease [44]. Thus, practically
all patients in our institution were HLA-matched be-
cause our donors wereHLA-identical siblings or unre-
lated donors, primarily selected based on a match in
HLA A, B and -DRB1.
One may question if functional alloreactive NK
cells exist post-HCT in the situation of an HLA-
match. We found at least 9 donors in our relatively
small study that expressed KIR for which they them-
selves lacked an HLA class I ligand (‘‘aberrant’’ KIR).
Most aberrant KIRs were expressed by NK cells that
coexpressed additional inhibitory receptors. Althoughand their alloreactive potential. (A) The numbers of NKG2A– LIR1– NK
and #28 before (pre Tx) and at several time points following HCT, com-
s had noHLA class I ligand (marked by an arrow). (B) CD107a expression
lls were measured by flow cytometry in subpopulations of the NKG2A–
ets indicated above the dot plots), expressing KIR for which the patients
s are indicated in the quadrants. KIR2DL2/L3/S21 or KIR3DL1/S11 gated
Analysis of dot plots gated on multiple KIR was restricted to NK cells
nt #21 KIR2DL2/L3/S21 and/or KIR3DL1/S11 and for #28 KIR3DL1/
Figure 7. Activating receptors on NK cells following KIR/HLA-ligand matched and mismatched HCT. The mean fluorescence index (MFI) was deter-
mined by flow cytometry for the activating receptors 2B4, NKG2D, NKp30, NKp44, and NKp46 expressed by NK cells from KIR/HLA-ligand mis-
matched and KIR/HLA-ligand matched transplanted patients before HCT (pre Tx) and at different time points following HCT. The numbers of
patients (n) in the KIR/HLA-ligand mismatched and matched groups for each time point are indicated on the right. Statistically significant differences
between the KIR/HLA-ligand mismatched and matched patients are indicated (*).
Biol Blood Marrow Transplant 16:469-481, 2010 479NKG2A–LIR1– NK Cells following HCTthis would prevent most autoreactivity against normal
cells, such NK cells may still mediate a significant
GVL effect because leukemia cells may express ligands
for activating NK receptors so that the total activating
signals may prevail over the inhibitory signals [9,11].
In addition, leukemia cells may lose single HLA class
I alleles that would make them sensitive for GVL ef-
fects by rare NK cell subsets [45]. We show that
such NK cells expressing aberrant KIR increase post-
HCT (eg, KIR3DL11 cells in patients #21 and #28;
Figure 6). Although NK cells lacking self-HLA class
I receptors are normally considered to be developmen-tally and functionally immature [24,46], the present
data and a study published recently [42] suggest that
NK cells expressing the HLA-mismatched KIRs, and
no other inhibitory receptors, may actually be func-
tional following HCT (Figure 6B). Nevertheless, we
cannot exclude that they are somewhat functionally
impaired, as has been suggested by another study in
a haploidentical setting [34]. Such single KIR1 NK
cells with alloreactive potential may be present in all
HLA-matched HCT-patients who are not positive
for all 3 KIR/HLA ligands (C1, C2, and Bw4). An in-
triguing hypothesis is that, even in the healthy donors,
480 Biol Blood Marrow Transplant 16:469-481, 2010S. Rathmann et al.such NK cells might have a ‘‘leukemia-protective’’ ef-
fect. Further experiments are needed to investigate
howNK education following stem cell transplantation
might differ from the physiological development of
NK cells.
Expression levels of the activating receptors
NKG2D, NKp30, NKp44, and NKp46 on NK cells
increased in both patient groups during the observation
period followingHCT (until day 168) (Figure 7).Most
remarkable was the rise in NKG2D-expression onNK
cells that could be observed in KIR/HLA-ligand mis-
matched patients around day 156 and in the KIR/
HLA-ligand matched patients around day 1112. In-
creased expression levels of NK activating receptors
at later time points following HCT may represent
a mechanism in maintaining remission following
HLA mismatched, as well as matched transplants.
In addition to NK cells, we also investigated the ex-
pression of NK receptors on other effector cell popula-
tions such asNKTcells,NKT-like cells, aswell as other
ab and gd T cells. It appears that NKG2A– LIR1–
NKT-like cells andNKG2A– LIR1– gdT cells express-
ing KIRs transiently increased following HCT
compared to the levels in the patient pre-HCT or those
seen in the donor. The vast majority of cytotoxic gd T
cells expressed CD94/NKG2A [4,47] and the
NKG2A– LIR1– phenotype on T cells is rather infre-
quent. Expression of broadly reactive inhibitory recep-
tors is restricted to T cells with a potential for
autoreactivity. These receptors downmodulate the acti-
vating signals from the TCR and protect from the auto-
immune capacity of these effector cells. In other words,
T cells expressing broadly reactive inhibitory receptors
need additional signals from the TCR to play a role in
GVH and GVL responses, and the antigenic specific-
ities of these cells depend on the T cell repertoire
of the particular donor. Our data showing relatively
few KIR-expressing T cells after HCT suggest that
such MHC unrestricted and potentially autoreactive
T cells are less important for the GVL effect than NK
cells.
In summary, our data suggest that NKG2A– LIR1–
NK cells are important effector cells in GVL. NK
cells, expressing only 1 inhibitory KIR for which the
patient has no ligand, maymediate GVL effects in hap-
loidentical, KIR/HLA-ligand mismatched, as well as
in HLA-matched, KIR/HLA-ligand mismatched
HCT patients. The function of such NK cells follow-
ing HCT needs to be compared to similar NK cells
present in normal donors, as well as to regular
NKG2A1 NK cells.ACKNOWLEDGMENTS
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